ACE inhibitory/sartany a zakażenie COVID-19: stanowiska naukowe ESC i ESH

Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers

This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it. Indeed, there is evidence from studies in animals suggesting that these medications might be rather protective against serious lung complications in patients with COVID-19 infection, but to date there is no data in humans.

The Council on Hypertension of the European Society of Cardiology wish to highlight the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak.

Statement of the European Society of Hypertension (ESH) on hypertension, Renin Angiotensin System blockers and COVID-19

The currently available data on COVID-19 infections do not a support a differential use of RAS blockers (ACEI or ARBs) in COVID-19 patients.

12-13 marca 2020

Dodaj komentarz